Curis, Inc. (CRIS)
| Previous close | 15.69 |
| Open | 15.34 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 12.75 - 15.52 |
| 52-week range | 0.38 - 17.49 |
| Volume | |
| Avg. volume | 25,980 |
| Market cap | 75.975M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Curis Announces Additional Data from TakeAim Leukemia Study
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.
- PR Newswire
Curis to Present Updated Data from the TakeAim Leukemia Study
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET.
- PR Newswire
Curis Provides First Quarter 2024 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.
